Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.46 |
| ▸ | BRAF | P15056 | 6/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872449 | 0.91 | KIT (0.48) | KITBRAFNOTUMMAOAMAOB | |
| SCHEMBL1488488 | 0.90 | NOTUM (0.43) | KITBRAFNOTUMMAOAMAOB | |
| SCHEMBL1488663 | 0.86 | NOTUM (0.41) | KITBRAFNOTUMMAOAMAOB | |
| SCHEMBL3873766 | 0.86 | KIT (0.59) | KITBRAFNOTUMBRD4CREBBP | |
| SCHEMBL13714573 | 0.83 | IRAK4 (0.39) | KITBRAFNOTUMAURKAAURKB | |
| SCHEMBL5176609 | 0.80 | KDR (0.50) | KITBRAFNOTUM | |
| SCHEMBL3875110 | 0.77 | KIT (0.61) | KITBRAFNOTUMBRD4CREBBP | |
| SCHEMBL1488991 | 0.76 | NOTUM (0.48) | KITBRAFNOTUMBRD4CREBBP | |
| SCHEMBL4036546 | 0.75 | KIT (0.53) | KITBRAFNOTUM | |
| SCHEMBL4037571 | 0.74 | KIT (0.50) | KITBRAFNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | claimed |
| EP-1807415-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | claimed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | claimed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | claimed |
| WO-2006048248-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE IMHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | claimed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
| EP-1807415-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | disclosed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006048248-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE IMHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | KDR, FLT4, FLT1 | KIT 83/4885BRAF 495/4885NOTUM 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.